Idylla™ NRAS-BRAF-EGFR S492R Mutation Assay (RUO)


About 50% of all metastatic colorectal tumors harbor RAS mutations¹. The frequency of NRAS mutations in exons 2, 3 and 4 is around 5%1. The frequency of BRAF mutations in mCRC is 8%¹.



The Idylla™ NRAS-BRAF-EGFR S492R Mutation Assay allows detection of NRAS, BRAF and EGFR 492 mutations directly from formalin-fixed paraffin-embedded (FFPE) tissue sections in approx. 2 hours with less than 2 minutes hands-on time.


  • Directly from FFPE tissue sections
  • Approx. 2 hours total turnaround time from sample to result
  • Less than 2 minutes hands-on time
  • Detection of 25 relevant mutations: 8 NRAS mutations in codons  12 and 13 (exon 2), 6 NRAS mutations in codons 59 and 61 (exon 3), 4 NRAS mutations in codons 117 and 146 (exon 4), 5 BRAF mutations in codon 600 (exon 15) and 2 EGFR mutations in codon 492 (exon 12)
  • Highly standardized
  • An average sensitivity of 1-5% based on research data
  • Contamination-controlled design


¹ Jean-Yves Douillard, M.D., Ph.D., Kelly S. Oliner, Ph.D., Salvatore Siena, M.D., et al. Panitumumab–FOLFOX4 Treatment and

RAS Mutations in Colorectal Cancer. N Engl J Med 2013;369:1023-34.

Highly standardized


The Idylla™ NRAS-BRAF-EGFR S492R Mutation Assay, performed on the Biocartis Idylla™ system, is an in vitro diagnostic test for the qualitative detection of mutations in codons 12, 13, 59, 61, 117, 146 of the NRAS oncogene, codon 600 of the BRAF oncogene and codon 492 of the EGFR gene. The Idylla™ NRAS-BRAF-EGFR S492R Mutation Assay directly liberates DNA from FFPE tissue of human colorectal cancer for subsequent real-time PCR amplification and detection.

Idylla™ NRAS-BRAF-EGFR S492R Mutation Assay is intended for Research Use Only.
Not for sale in the USA and Canada.


For product availability in your country contact us via customerservice@biocartis.com.